Ubs Group Ag Kiora Pharmaceuticals Inc Transaction History

Ubs Group Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$0.36 - $0.68 $10,268 - $19,395	28,523 Added 8565.47%	28,856 $13,000
Q1 2022 May 16, 2022	SELL	$0.54 - $1.27 $10,875 - $25,577	-20,140 Reduced 98.37%	333 $0
Q4 2021 Feb 14, 2022	BUY	$0.86 - $2.11 $17,606 - $43,198	20,473 New	20,473 $31,000

Ticker KPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 919,078
Market Cap $3.1M
Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.